Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1

Archives of Neurology

Volumn 68, Issue 1, 2011, Pages 37-44

  Heatwole, Chad R ^a   Eichinger, Katy J ^a   Friedman, Deborah I ^a   Hilbert, James E ^a   Jackson, Carlayne E ^b   Logigian, Eric L ^a   Martens, William B ^a   McDermott, Michael P ^a   Pandya, Shree K ^a   Quinn, Christine ^a   Smirnow, Alexis M ^a   Thornton, Charles A ^a   Moxley III, Richard T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; MECASERMIN RINFABATE; SOMATOMEDIN C; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOGLYCEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LEAN BODY WEIGHT; MALE; MUSCLE MASS; MUSCLE STRENGTH; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 1; PAPILLEDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; SWELLING; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; RECOMBINANT PROTEINS;

EID: 78651312601     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2010.227     Document Type: Article

References (32)

1. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;69(2):385.
2. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol. 2002;157(1):137-148.
3. Shavlakadze T, White J, Hoh JF, Rosenthal N, Grounds MD. Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Mol Ther. 2004;10(5):829-843.
4. Furling D, Marette A, Puymirat J. Insulin-like growth factor I circumvents defective insulin action in human myotonic dystrophy skeletal muscle cells. Endocrinology. 1999;140(9):4244-4250.
5. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, et al. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy: a clinical research center study. J Clin Endocrinol Metab. 1995;80(12):3715-3723.
6. Camacho-Hübner C, Rose S, Preece MA, et al. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrinol Metab. 2006;91(4):1246-1253.
7. Boonen S, Rosen C, Bouillon R, et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab. 2002;87(4):1593-1599.
8. Debroy MA, Wolf SE, Zhang XJ, et al. Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. J Trauma. 1999;47(5):904-911.
9. Clemmons DR, Sleevi M, Allan G, Sommer A. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes. J Clin Endocrinol Metab. 2007;92(7):2652-2658. (Pubitemid 47037372)
10. Adams S, Moore J, Chu S, et al. Pharmacokinetics and bioavailability of rhIGF-I/ IGFBP-3 in the rat and monkey. Prog Growth Factor Res. 1995;6(2-4):347-356.
11. Bagi CM, Brommage R, Deleon L, Adams S, Rosen D, Sommer A. Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized rats. J Bone Miner Res. 1994;9(8):1301-1312. (Pubitemid 24238361)
12. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein- 3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab. 2000;85(4):1518-1524.
13. Personius KE, Pandya S, King WM, Tawil R, McDermott MP; The FSH DY Group. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. Phys Ther. 1994;74(3):253-263.
14. Moxley RT III, Logigian EL, Martens WB, et al. Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve. 2007;36(3):320-328.
15. Logigian EL, Moxley RT IV, Blood CL, et al. Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1. Neurology. 2004;62(7):1081-1089.
16. Logigian EL, Blood CL, Dilek N, et al. Quantitative analysis of the "warm-up" phenomenon in myotonic dystrophy type 1. Muscle Nerve. 2005;32(1):35-42.
17. Buddenberg LA, Davis C. Test-retest reliability of the Purdue pegboard test. Am J Occup Ther. 2000;54(5):555-558.
18. Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. Arch Phys Med Rehabil. 1969;50(6):311-319.
19. Kierkegaard M, Tollbäck A. Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromuscul Disord. 2007;17(11-12):943-949.
20. Griggs RC, Pandya S, Florence JM, et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology. 1989;39(2 pt 1):219-222. (Pubitemid 19059308)
21. Hansen RD, Raja C, Aslani A, Smith RC, Allen BJ. Determination of skeletal muscle and fat-free mass by nuclear and dual-energy x-ray absorptiometry methods in men and women aged 51-84 y (1-3). Am J Clin Nutr. 1999;70(2):228-233. (Pubitemid 29347568)
22. Forbes GB, Griggs RC, Moxley RT III, Thornton CT, Tawil R. K-40 and dual-energy X-ray absorptiometry estimates of lean weight compared: normals and patients with neuromuscular disease. Ann N Y Acad Sci. 2000;904:111-114. (Pubitemid 30389168)
23. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. Oxford, England: Oxford University Press; 1998.
24. Wiklund IK, Fullerton S, Hawkey CJ, et al. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol. 2003;38(9):947-954.
25. Longstreth GF, Bolus R, Naliboff B, et al. Impact of irritable bowel syndrome on patients' lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. Eur J Gastroenterol Hepatol. 2005;17(4):411-420.
26. Juul A, Holm K, Kastrup KW, et al. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab. 1997;82(8):2497-2502.
27. Griggs RC, Jozefowicz R, Kingston W, Nair KS, Herr BE, Halliday D. Mechanism of muscle wasting in myotonic dystrophy. Ann Neurol. 1990;27(5):505-512.
28. Griggs RC, Rennie MJ. Muscle wasting in muscular dystrophy: decreased protein synthesis or increased degradation? Ann Neurol. 1983;13(2):125-132. (Pubitemid 13188205)
29. Halliday D, Ford GC, Edwards RH, Rennie MJ, Griggs RC. In vivo estimation of muscle protein synthesis in myotonic dystrophy. Ann Neurol. 1985;17(1):65-69.
30. Moxley RT III. Myotonic muscular dystrophy. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of Clinical Neurology. Vol 2. New York, NY: Elsevier Science Publishers; 1992:209-259.
31. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center: insulin-like growth factors. N Engl J Med. 1997;336(9):633-640.
32. Carrasco M, Canicio J, Palacín M, Zorzano A, Kaliman P. Identification of intracellular signaling pathways that induce myotonic dystrophy protein kinase expression during myogenesis. Endocrinology. 2002;143(8):3017-3025.